High-dose-rate Brachytherapy as Adjuvant Local rEirradiation for Salvage Treatment of Recurrent breAst cancer (BALESTRA): a retrospective mono-institutional study
| Autor: | Raffaella Cambria, R. Spoto, Andrea Vavassori, Iacopo Cavallo, Roberto Orecchia, Samantha Dicuonzo, Roberta Lazzari, Cristiana Fodor, Maria Cristina Leonardi, Anna Morra, Paolo Veronesi, Stefania Comi, Mattia Intra, Alberto Luini, Giulia Riva, Federica Cattani, Viviana Galimberti, Barbara Alicja Jereczek-Fossa |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0106 biological sciences
medicine.medical_specialty medicine.medical_treatment Brachytherapy 01 natural sciences Medicine reirradiation Radiology Nuclear Medicine and imaging Survival rate Original Paper business.industry 010401 analytical chemistry Soft tissue High-Dose Rate Brachytherapy 0104 chemical sciences Surgery Catheter breast cancer recurrence Oncology Cohort Implant interstitial HDR brachytherapy business Quadrantectomy 010606 plant biology & botany |
| Zdroj: | Journal of Contemporary Brachytherapy Journal of Contemporary Brachytherapy, Vol 12, Iss 3, Pp 207-215 (2020) |
| ISSN: | 1689-832X |
| Popis: | Purpose To evaluate clinical results of catheter-based interstitial high-dose-rate (HDR) brachytherapy (BT) as adjuvant treatment in previously irradiated recurrent breast cancer. Material and methods Between January 2011 and September 2015, 31 consecutive patients with histologically confirmed recurrent breast cancer after conservative surgery and conventional whole breast radiotherapy, were retreated with a second conservative surgical resection and reirradiated with adjuvant interstitial HDR-BT. None of the brachytherapy implant was performed during the quadrantectomy procedure. A dose of 34 Gy in 10 fractions, 2 fractions per day, with a minimal interval of 6 hours was delivered. Results At the time of the implant, the median age of patients was 59.7 years (range, 39.3-74.9 years). The median time from first treatment until BT for local recurrence was 11.9 years (range, 2.5-27.8 years). The median interval between salvage surgery and BT was 3.6 months (range, 1-8.2 months). No acute epidermitis or soft tissue side effects higher than grade 2 were recorded, with good cosmetic results in all patients. Most of the patients presented grade 1-2 late side effects. Only one patient developed grade 3 liponecrosis. After a median follow-up of 73.7 months (range, 28.8-102.4 months), the overall survival and cancer specific survival were 87.1% and 90.3%, respectively; 5-year local control and 5-year progression-free survival rate were 90.3% and 83.9%, respectively. Conclusions Our preliminary analysis showed that HDR-BT is a feasible treatment for partial breast reirradiation offering very low complications rate and fast procedure. Higher patients' cohort is warranted in order to define the role of this treatment modality in the breast conservative management of local recurrence. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|